Delonix Bioworks is a Shanghai-based startup using synthetic biology to design bacteria to act as safer and more effective vaccines against bacterial infections and cancer.
The Delonix team has developed a novel approach that builds on the established concept of live attenuated bacteria and combines it with the latest developments in synthetic biology. Delonix’s synthetic biology and antigen discovery platforms enable rational design and programming of bacteria into vaccines that are expected to be safer and more effective.
Initial lead programs will target anti-microbial resistance (AMR), including resistant bacteria such as methicillin-resistant Staphylococcus aureus (MRSA). The company says that antimicrobial resistance is projected to cause up to 10 million deaths annually by 2050.
The company recently raised $14m in seed funding to accelerate the building of its platforms and advance its pipelines of synthetic vaccines to clinical trials.
Subscribe for alerts on new companies featured on Startups.Bio
Aulos Bioscience aims to revolutionize cancer patient care through the development of pioneering Interleukin-2 therapeutics for the treatment of solid tumor cancers. Interleukin-2 or IL-2 …
Code Bio is using its novel targeted non-viral delivery platform to develop genetic medicines for serious and life-threatening diseases such as Type 1 Diabetes and …
Muna Therapeutics aims to preserve brain function and enhance resilience to neurodegenerative diseases. The company engages in the discovery and development of novel therapies that …
Glyphic Biotechnologies is an MIT spin-out aiming to accelerate the critical but slow step of sequencing new proteins, potentially cutting drug development times down by …
ImmuneID is a precision immunology company that has developed a genome-wide, high-throughput platform to provide an understanding of individual immune responses. ImmuneID's aiSPIRE platform screens billions of …
Flare uses a “switch-site based drug discovery approach” to develop a pipeline of therapeutic programs that target pivotal cancer drivers such as transcription factor dysregulation …
